Prespecified 5-year follow-up of the phase III NATALEE trial in HR-positive/HER2-negative early breast cancer: adjuvant ribociclib plus NSAI vs NSAI alone sustained the iDFS benefit (HR 0.716; median follow-up 55.4 months); overall survival HR 0.800, not yet mature.
RCT
Crown et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival